TIVC · Valion Bio, Inc.

Tivic Health Systems, Inc. has undergone a decisive strategic transformation, shifting from a diversified bioelectronic medical device company to a late-stage biopharmaceutical enterprise anchored by Entolimod, a recombinant TLR5 agonist with robust preclinical and clinical validation. This pivot — executed in fiscal year 2025 — involved the deliberate divestment of its consumer health business (ClearUP) and suspension of prescription bioelectronic development (ncVNS), allowing full resource concentration on Entolimod’s regulatory pathway. The asset’s value proposition is reinforced by FDA Fast Track and Orphan Drug designations for acute radiation syndrome (ARS), and by $140 million in cumulative prior funding, including $35.6 million in non-dilutive support from U.S. government agencies such as the Department of Defense and NIH. This positions Tivic within a high-stakes, mission-critical market where successful BLA submission could unlock government procurement contracts and emergency-use authorizations internationally. Financially, the company operates under significant pressure: its auditors’ report dated March 30, 2026 explicitly raises substantial doubt about its ability to continue as a going concern, underscoring the urgency of capital deployment. The S-1 filing directly addresses this by registering 956,222 shares for resale by Tumim Stone Capital — 519,210 shares issuable under a $50 million committed equity line and 437,012 shares underlying a pre-funded warrant. Critically, the equity line is not a simple forward purchase agreement; it employs a dynamic VWAP-based pricing mechanism (95% for three-day periods, 97% for one-day periods) tied to trading volume caps and subject to both a 9.99% beneficial ownership blocker and a hard Exchange Cap of 506,848 shares (19.99% of pre-deal shares). This structure introduces meaningful execution risk: while Tumim has committed capital, the Company retains full discretion over timing and size of draws, and cannot exceed the cap without stockholder approval — a potential bottleneck during critical BLA preparation. Proceeds from any sales will fund general corporate purposes, but management holds broad, unqualified discretion over allocation, creating governance risk for investors. The launch of Velocity Bioworks as a wholly owned CDMO adds a second strategic pillar — de-risking internal manufacturing while generating external revenue — though it remains in early commercial stages. Collectively, this offering reflects a high-stakes financing maneuver for a company in active transition: its success hinges not only on execution of the equity line but on disciplined progress toward BLA submission, validation of the CDMO model, and navigation of material dilution and governance constraints embedded in the Tumim agreement. For investors, the primary risk is not just scientific or regulatory uncertainty, but whether the capital access mechanism itself can deliver sufficient, timely, and non-dilutive-enough funding to sustain operations through pivotal milestones.